Methodist Richardson Medical Center
Dallas, Texas, 75082, United States
NCT Number: NCT06096064
Unfractionated heparin (UFH) is an anticoagulant to prevent thrombus formation or worsening of an existing thrombus. It is indicated for patients with deep vein thrombosis/pulmonary embolism (DVT/PE) or acute coronary syndrome (ACS). Unfractionated heparin treatment consists of an initial bolus followed by a continuous infusion that is adjusted based on the patient's subsequent partial thromboplastin time (PTT) levels
Looking for future studies?
Notify Me18 year–75 year
All sexes
Observational
Dallas, Texas, 75082, United States
Unfractionated heparin is classified as a high-alert medication in the acute care setting.3 Therapeutic anticoagulation is a high priority for healthcare teams because the impacts of inadequate anticoagulation can lead to life threatening events such as a major bleed or thrombus formation and/or death.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 30 Days
Appropriate anticoagulation management will be measured using Percent time in therapeutic range based on aPTT levels
Methodist Health System
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06779162
Anticoagulation, Lung Transplantation
Prague, Czech Republic, Czechia
View Trial DetailsNCT03861286
Cardiopulmonary Bypass Surgery, Unfractionated Heparin
London, United Kingdom
View Trial DetailsNCT07365670
Anti Xa Activity, Cardiovascular Abnormalities
View Trial Details